DIGOXIN injection adverse reactions: Difference between revisions
(Created page with "__NOTOC__ {{Digoxin}} {{CMG}}; {{AE}} {{AK}} '''''For patient information, click <u>here'''''</u>. 6 ADVERSE REACTIONS=== == The following ...") |
No edit summary |
||
| Line 4: | Line 4: | ||
'''''For patient information, click <u>[[Digoxin (patient information)|here]]'''''</u>. | '''''For patient information, click <u>[[Digoxin (patient information)|here]]'''''</u>. | ||
== | ==6 ADVERSE REACTIONS== | ||
The following adverse reactions are included in more detail in the Warnings and Precautions section of the label: | The following adverse reactions are included in more detail in the Warnings and Precautions section of the label: | ||
Revision as of 20:43, 27 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
For patient information, click here.
6 ADVERSE REACTIONS
The following adverse reactions are included in more detail in the Warnings and Precautions section of the label:
• Cardiac arrhythmias [see Warnings and Precautions (5.1, 5.2)]
• Digoxin Toxicity [see Warnings and Precautions (5.3)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In general, the adverse reactions of digoxin are dose-dependent and occur at doses higher than those needed to achieve a therapeutic effect. Hence, adverse reactions are less common when digoxin is used within the recommended dose range, is maintained within the therapeutic serum concentration range, and when there is careful attention to concurrent medications and conditions.
In the DIG trial (a trial investigating the effect of digoxin on mortality and morbidity in patients with heart failure), the incidence of hospitalization for suspected digoxin toxicity was 2% in patients taking digoxin compared to 0.9% in patients taking placebo [see Clinical Studies (14.1)].
The overall incidence of adverse reactions with digoxin has been reported as 5 to 20%, with 15 to 20% of adverse events considered serious. Cardiac toxicity accounts for about one-half, gastrointestinal disturbances for about one-fourth, and CNS and other toxicity for about one-fourth of these adverse events.
Gastrointestinal: In addition to nausea and vomiting, the use of digoxin has been associated with abdominal pain, intestinal ischemia, and hemorrhagic necrosis of the intestines.
CNS: Digoxin can cause headache, weakness, dizziness, apathy, confusion, and mental disturbances (such as anxiety, depression, delirium, and hallucination).
Other: Gynecomastia has been occasionally observed following the prolonged use of digoxin. Thrombocytopenia and maculopapular rash and other skin reactions have been rarely observed.
References
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=58f45aba-ff6f-43cc-bb88-be40a9f7beda